MicroPort Scientific Corporation provided group earnings guidance for the year ended December 31, 2017. The board of directors of the company announced that, the Group is expected to record approximately 30% to 35% increase in the profit attributable to equity shareholders of the company for the year ended December 31, 2017 as compared with that for the year ended December 31, 2016. The significant increase in the unaudited profit attributable to equity shareholders of the company for the year ended December 31, 2017 is principally attributable to a significant growth in revenue from the cardiovascular and endovascular segments in the PRC market, and in particular, a significant revenue growth of third generation coronary stent product Firehawk™ Drug Eluting Stent; and a substantial reduction of net loss of the OrthoRecon business due to the improvement in revenue and gross margin.